TFX

Teleflex Inc. Q1 2008 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 30, 2008. Teleflex Inc. is a diversified manufacturer of specialty-engineered products serving the medical, aerospace, and commercial industries. The quarter reflects the full impact of the October 2007 acquisition of Arrow International, Inc. ($2.1 billion), which significantly expanded the Medical segment. The company also divested its automotive and industrial driver controls businesses in late 2007, which are reported as discontinued operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 37% year-over-year. Acquisitions (primarily Arrow) contributed 36% of this growth, and foreign currency fluctuations added 4%. Core revenues declined 2% due to a sharp drop in auxiliary power unit sales for the North American truck market and weaker sales of certain medical products.
• Profitability: While gross margin improved to 38.5% due to higher-margin Arrow products, Net Income dropped 48% to $22.9 million. This decline was driven by a significant increase in interest expense ($31.1 million vs. $9.2 million) related to Arrow acquisition debt, higher restructuring charges ($8.9 million vs. $0.4 million), and the absence of discontinued operations income ($10.4 million in Q1 2007).
• Cash Flow: Operating cash flow turned negative ($6.0 million used) compared to a positive $38.9 million in the prior year. This was primarily due to a $47.4 million tax payment related to prior divestitures and a $32.2 million increase in accounts receivable.
• Segment Performance: The Medical segment revenue grew 65% and operating profit grew 46%. The Aerospace segment revenue grew 17%, but operating profit declined 2%. The Commercial segment revenue declined 1% and operating profit fell 48%.

Outlook, Risks, and Management Commentary

• Restructuring: The company incurred $8.0 million in restructuring charges in Q1 2008 related to the Arrow integration. Management expects to incur an additional $18.0 million to $22.0 million in restructuring costs in 2008 and 2009 for this program. Future costs for the 2006 restructuring program are estimated between $0.7 million and $1.0 million.
• Regulatory Matters: The FDA issued a corporate warning letter to Arrow International in October 2007 regarding quality system deficiencies. Teleflex has submitted a corrective action plan and expects to complete remediation by the end of 2008. Failure to satisfy the FDA could result in product seizures or injunctions.
• Capital Allocation: The company has a $300 million stock repurchase authorization but has not purchased any shares through March 30, 2008, due to debt covenants and cash requirements for acquisitions and operations.
• Dividends: Dividends per share increased to $0.320 from $0.285 in the prior year.

Investor Verification Checklist

• Arrow Integration Costs: Verify the timeline and total cost of the Arrow integration plan, specifically the $18M-$22M future restructuring estimate.
• FDA Remediation: Monitor the status of the FDA corrective action plan for Arrow International to ensure no further regulatory sanctions occur.
• Core Revenue Trends: Assess the sustainability of the 2% core revenue decline, particularly the impact of the North American truck market on auxiliary power unit sales.
• Interest Expense: Confirm the trajectory of interest expenses given the $1.68 billion debt load and the impact on future earnings.
• Cash Flow Recovery: Watch for the normalization of operating cash flows following the large one-time tax payment related to divestitures.